Advertisement Pharmaceutical Business review - Page 526 of 5223 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 17, 2024

Astria Therapeutics’ navenibart gains orphan medicinal status from EC

Astria Therapeutics received the European Commission's orphan medicinal product designation (OMPD) for navenibart (STAR-0215) to treat hereditary angioedema (HAE).

The clinical trial has shown positive results, with the antibody demonstrating a favourable safety and tolerability profile. Credit: National Cancer Institute on Unsplash.